Skip to main content
Premium Trial:

Request an Annual Quote

Fabric Genomics, Genomenon Sign Comarketing Deal

NEW YORK (GenomeWeb) — Fabric Genomics and Genomenon announced today that they have signed an agreement to integrate their respective genomic interpretation technologies and co-market the combined offering.

The deal will join Oakland, California-based Fabric's Enterprise platform for next-generation sequencing data analysis, interpretation, and clinical reporting with Genomenon's Mastermind literature search engine.

Last month, Ann Arbor-based Genomenon released the latest version of the Mastermind search engine, which indexes approximately 4.1 million genomic variants from supplemental data found in scientific publications.

The companies said that the integration of their technologies will allow users to see which candidate variants have any related scientific literature entries with direct access to a prioritized list of relevant articles during variant interpretation and classification.

Additional terms of the deal were not disclosed.

"Combining Fabric's algorithmic genomic analysis with Genomenon's literature search further enhances our approach to scaling genomic interpretation," Fabric President and CEO Martin Reese said in a statement. "Integrating Mastermind within our interpretation platform will help our users minimize the manual effort it takes to select and read relevant evidence-based papers."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more